In the field of blood tumors, Deqi Pharmaceutical officially launched strategic cooperation
On May 29th, Deqi Pharmaceutical (Deqi) and Nasdaq-listed Karyopharm Therapeutics (Karyopharm) signed an agreement at the Ritz-Carlton Shanghai, Pudong, officially launched a strategic partnership to jointly develop four oral clinical development stages. Innovative drugs.
The four compounds include three SINE XPO1 antagonists in different clinical development stages: Selinexor, Eltanexor, Verdinexor; and a PAK4 and NAMPT dual target inhibitor KPT-9274. Deqi Pharmaceutical will have the right to develop and commercialize all tumor indications for Selinexor and Eltanexor in mainland China and Macau, as well as develop and commercialize KPT-9274 in China, Macau, Taiwan, Hong Kong, Korea and the Association of Southeast Asian Nations. Tumor indications, Verdinexor non-tumor indications. If Karyopharm chooses to develop and commercialize Verdinexor's oncology, Deqi has the right to develop and commercialize Verdinexor's indications for cancer in the agreed area.
In four projects, Selinexor has entered clinical Phase II and Phase III studies in multiple blood and solid tumors including multiple myeloma, diffuse large B-cell lymphoma, and liposarcoma, treating more than 2,400 patients and More than 40 clinical projects are underway. In April 2018, the US FDA granted Selinexor the eligibility for a rapid review channel in refractory relapsed multiple myeloma indications.
Dr. Mei Jianming, Chairman of Deqi Pharmaceutical Co., Ltd. said that Deqi hopes to continue to target China's many tumors and other serious diseases that endanger life and quality of life through cooperation with leading companies such as Karyopharm and global innovative drugs. Prospects for China and the Asia Pacific market. Previously, Deqi cooperated with American New Base Company (English name: Celgene) very smoothly. The first cooperation project, ATG-008 project for the treatment of advanced hepatocellular carcinoma, is conducting international multi-center clinical trials in China, Taiwan and Korea. . This in-depth cooperation with Karyopharm marks a milestone for Deqi's formal entry into the field of hematologic malignancies and non-neoplastic diseases. “We will submit the first product of Selinexor in mainland China in the third quarter of this year. The cooperation between our two parties is not a simple project introduction, but a joint development of multiple products, multiple dimensions and multiple regions. However, our ultimate goal is to develop Chinese and Asia-Pacific patients as soon as possible through cooperative development."
Karyopharm focuses on the development of unique drugs in the world, especially in the field of hematological malignancies. Its innovative drugs for nuclear export protein inhibitor related targets have entered the final sprint stage before the market after several years of development. In addition, this series of drugs has shown great development potential in different diseases such as solid tumors, influenza, respiratory inflammation, and other viruses. “With the introduction of the Deqi platform, Karyopharm's new drug project will be rapidly developed and commercialized. Deqi has extensive regulatory and clinical research and development experience in China and other Asia-Pacific countries and regions. This comprehensive cooperation has enriched our global R&D and commercialization will significantly improve the development and commercialization of our products in China and the Asia-Pacific market, and benefit more Chinese and Asian patients,†said Dr. Michael Kauffman, CEO of Karyopharm.
About Deqi
Deqi Pharmaceuticals is an innovative biopharmaceutical company focused on the development and sale of new drugs, focusing on addressing unmet medical needs in Asia and striving to provide the most advanced and leading anticancer drugs for patients in China and Asia Pacific. On April 13, 2017, the global leader in innovative pharmaceuticals, New Base Pharmaceuticals (Nasdaq: CELG), became a long-term strategic partner of Deqi Pharmaceutical and merged into Deqi. At present, several projects of Deqi Medicine are in the clinical phase 2/3 development stage. The Asia-Pacific multicenter liver cancer clinical trial of the main research and development pipeline product TORC1/TORC2 dual target inhibitor ATG-008 has been carried out in various regions including China, Taiwan and South Korea.
About Karyopharm Therapeutics
Karyopharm is a biopharmaceutical company focused on the development of innovative drugs worldwide. The company develops innovative drugs with nuclear export protein inhibitor-related targets, and its SINE compounds work by binding to and inhibiting the nuclear export protein XPO1 (also known as CRM1). In addition to treating a variety of tumors by single-agent and combination therapy, the company's SINE compounds also exhibit biological activity in various diseases such as neurodegenerative diseases, inflammation, autoimmune diseases, and viral infections. Founded by Dr. Sharon Shacham, Karyopharm currently has multiple drugs in clinical trials and preclinical studies.
Hypertension medication,L-lysine Hydrochloride Powder,Bulk L-Lysine Powder,Taurine Buy Online,
Human APIs - Blood Pressure raw , APIs Raw powder , Antipyretic And Analgesic , Antibiotic & Antibacterial
Now we have 3 GMP standard workshop, Meanwhile, the factory is equipped with the researching and quality inspection centre, with strong technology research and development strength. We also have 3 salesdepartments over 30 people and sell our products all over the world.
For customer`s needs, OEM service is also acceptable. If you have a good idea in new product production but lack of laboratory device and human resource, we are glad to solve this problem for you. Sincerely hope to strengthen exchanges and cooperation with friends from both home and abroad.
Hypertension medication,L-lysine Hydrochloride Powder,Bulk L-Lysine Powder,Taurine Buy Online
Xi'an Henrikang Biotech Co.,Ltd , https://www.xianhenrikangbio.com